BLAINJECTIONINJECTABLE
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIMERLI (ranibizumab-eqrn) by Novartis is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2022.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMERLI (ranibizumab-eqrn) is a biosimilar monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), approved by the FDA in August 2022. It is indicated for retinal and ocular conditions where VEGF-driven neovascularization drives vision loss. The drug works by binding and neutralizing VEGF, preventing abnormal blood vessel growth in the eye.
$0.082BPart D
PeakEarly-stage biosimilar in peak adoption phase with modest Part D claims, indicating growing market penetration against established reference products; commercial team likely focused on payer education and provider conversion.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CIMERLI roles emphasize commercial execution in a competitive biosimilar space where differentiation is cost-based and payer-driven rather than clinical. Career growth depends on ability to drive formulary adoption, manage payer contracts, and convert providers from entrenched competitors in the mature anti-VEGF market.
Brand Manager
Worked on CIMERLI at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.